Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

• Status: Terminated
• Trial end date: 2015-05-29
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Adalimumab; Etanercept

Criteria

Inclusion Criteria:

• Moderate to severe plaque psoriasis

• Loss of satisfactory response to adalimumab

• Currently receiving or recently discontinued treatment with adalimumab

Exclusion Criteria:

• Active skin conditions that would interfere with evaluations of the effect of investigational product on psoriasis

• Serious medical conditions